You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.
SBC: NEURODON, LLC Topic: NIDDKThe overall goal of this collaborative project between Neurodon and Indiana University School of Medicine is the development of compounds that will offer disease-modifying treatments for type 1 (T1D) and type 2 diabetes (T2D) mellitus, a sorely unmet need. In this initial STTR project, we will use our expertise in medicinal chemistry, cell biology, and diabetes pathophysiology to functionally test ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates
SBC: Cellia Science, Inc. Topic: NIBIBProject Summary/Abstract Bone marrow aspirates are critical to the diagnosis, staging, and monitoring of hematologic conditions and cancers (e.g., leukemia, aplastic anemia, sickle cell disease, and metastasis of solid tumors), but 8-50% of aspirations are unsuccessful due to operator technique, hemodilution, or underlying pathology. Because this process is manual and error-prone, there is an oppo ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia
SBC: FGF Therapeutics INC. Topic: NIAMSAbstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
SBC: EPIVAX, INC. Topic: NIAIDABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Portable Scaled Sample Preparation Device for Concentration and Recovery of Bacterial Contaminants
SBC: VIC FOUNDRY INC Topic: NIAIDProject SummaryThe overall goal of this SBIR project is to establish the technical feasibility for commercialization of a patent-pending sample preparation technology that concentrates and recovers microbial contaminants from appropriately scaled water samples. The proposed product is affordable, versatile, reusable, portable, and automated device with no moving parts, suitable for on-site or in-f ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic Cartridge for Point-of-Care Hematology Analysis
SBC: Cellia Science, Inc. Topic: NHLBIProject Summary/Abstract Evaluation for neutropenia and/or thrombocytopenia requires a 5-part white blood cell (WBC) differential with platelet count. Currently, instruments capable of these measurements must be operated in a CLIA-certified laboratory and rely on complex workflows involving multiple reagents, extensive calibration and maintenance, and operation by highly trained personnel. Turnaro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease
SBC: NEURODON, LLC Topic: NIAIn this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Injectable 3-month buprenorphine PLGA microparticle formulation
SBC: AKINA, INC. Topic: NIDAPROJECT SUMMARYThe objective of this Phase I study is to develop a 3-month delivery buprenorphine formulation for treating opioid use disorder (OUD). Developing a long-acting injectable buprenorphine formulation is urgently necessary for treating OUD. Currently, only two 1-month buprenorphine injectable formulations, Sublocade® and Brixadi®, are approved by the U.S. Food and Drug Administration ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy
SBC: OpalGenix, Inc. Topic: NIDAPROJECT SUMMARY: Opioid Use Disorder (OUD) in pregnant women, Neonatal Opioid Withdrawal Syndrome (NOWS) and associated hospital costs have dramatically increased in the past decade, with an American child is born suffering from NOWS every 15 minutes. The ongoing opioid epidemic is further worsened by the COVID- 19 pandemic. Despite medication treatment for OUD with buprenorphine or methadone, the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions
SBC: OpalGenix, Inc. Topic: NHLBIPROJECT SUMMARY Thoracic surgery (TS), especially pneumonectomy, lobectomy and segmentectomy, are common and very painful surgeries for lung lesions with high incidence of uncontrolled acute surgical pain, chronic post- thoracotomy pain and excessive opioid use. Those with poorly controlled acute surgical pain are at risk for chronic post-surgical pain (CPSP), long-term opioid use and opioid addic ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health